QPS Holdings Marks 30 Years of Innovation and Global Growth in Contract Research Services
QPS Celebrates 30th Anniversary NEWARK, Del.--(BUSINESS WIRE)--QPS Holdings, LLC (QPS), a renowned contract research organization (CRO) specializing in bioanalysis and clinical trials, is marking its 30th anniversary in 2025. Founded by Dr. Benjamin Chien in 1995 to provide high-quality bioanalytical liquid chromatography with tandem mass spectrometry (LC-MS/MS) contract services, QPS has evolved into a global leader in the field. The company's growth trajectory includes expanding from a single office in Delaware, USA, to eight locations across the United States, European Union, Asia, India, and Australia. This expansion has also seen QPS build a clinical trial network of over 700 sites, further solidifying its position in the industry. QPS began as a trio dedicated to small molecule bioanalysis and has blossomed into a global CRO with a workforce exceeding 1,200 employees. "Celebrating 30 years is a significant milestone for QPS, and I am incredibly proud of our hard-working and innovative team. Their dedication is the backbone of our success, and I am deeply grateful for their contributions," stated Dr. Benjamin Chien, founder and CEO of QPS. Dr. Chien emphasized the company's role in providing specialized scientific expertise to the pharmaceutical and biotechnology sectors. "QPS equips the industry with the best instruments, platforms, and processes necessary to support drug discovery and development programs. Our facilities around the world are designed to handle complex studies in areas such as obesity, type 2 diabetes, oncology, central nervous system (CNS) diseases, cell and gene therapy, and more." From its outset, QPS has continuously expanded its service portfolio to meet the diverse needs of clients. The company now offers a comprehensive range of services, including pharmacology, drug metabolism and pharmacokinetics (DMPK), toxicology, bioanalysis, translational medicine, leukopaks, peripheral blood mononuclear cells (PBMCs), cell therapy products, clinical trials, and central laboratory services. QPS is distinguished by its high-quality data, technical expertise, adherence to study timelines, collaborative solutions, and a customer-focused approach. Moving forward, the organization plans to maintain its commitment to delivering tailor-made research services that expedite pharmaceutical advancements worldwide. About QPS Holdings, LLC QPS Holdings, LLC is a global, full-service, Good Laboratory Practice (GLP) and Good Clinical Practice (GCP)-compliant CRO. The company has been at the forefront of discovery, bioanalysis, preclinical, and clinical drug development services since 1995. What started as a small bioanalysis firm has transformed into a robust CRO with a global presence and over 1,200 employees. QPS currently provides an extensive array of pharmaceutical contract R&D services, with particular strengths in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks, PBMCs, cell therapy products, clinical trials, and clinical research services. QPS is acclaimed for its rigorous quality standards, technical prowess, flexible research methods, and client satisfaction. The organization continually invests in enhancing capacities and resources to ensure it meets the evolving demands of its clients. For more information, visit www.qps.com or email info@qps.com.